ArticleClinical and experimental hepatology2025
Annexin A2 as a marker for hepatocellular carcinoma detection among patients with hepatitis C virus-related liver cirrhosis after HCV treatment using directly acting antivirals.
Article in Clinical and experimental hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim of the study: Hepatocellular carcinoma (HCC) is considered the sixth most prevalent malignant tumor, while it ranks first in Egypt. Early detection of HCC is of great value, as early stages can be treated with curative modalities. Current surveillance programs depend on ultrasonography and α-fetoprotein (AFP) measurement, but both have notable limitations. This study aimed to investigate the potential role of annexin A2 in HCC detection. Material and methods: The present study included four groups: Group A: early hepatocellular carcinoma, BCLC stages 0 and A; Group B: advanced hepatocellular carcinoma, BCLC stage C; Group C: liver cirrhosis without HCC; Group D: healthy participants as a control group. Chronic hepatitis C was the cause of cirrhosis in three groups (A, B, and C). All of them attained a sustained virological response (SVR) after receiving treatment with direct-acting antiviral medications (DAAs). Both serum AFP and annexin A2 were measured in all included subjects. Results: One hundred subjects were included, 25 in each group. Annexin A2 levels were significantly higher in early- and advanced-stage HCC participants. Serum annexin A2 level was an excellent discriminator of early HCC, with an area under the ROC curve (AUC) of 0.934. The cut-off point > 7.7 ng/ml had a sensitivity of 96.00%, a specificity of 88%, a positive predictive value (PPV) of 88.9%, and a negative predictive value (NPV) of 95.7% ( Conclusions: Serum annexin A2 is a promising biomarker that can improve the sensitivity of HCC detection among patients with liver cirrhosis after HCV eradication using DAAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.